Literature DB >> 10517870

The hybridoma revolution: an offshoot of basic research.

C Milstein1.   

Abstract

In this narrative, I describe how my interest in the nature and origin of antibody diversity led me to tackle the problem by using somatic cell genetic techniques. The first hybridoma (an immortal antibody-secreting cell line derived by fusion of a short-lived lymphocyte and a myeloma cell line) was an offshoot of this approach. Although not intended for such purposes, it soon became obvious that this invention had widespread potential in basic research and industry. Indeed, the technique opened new inroads into the study of complex biological substances and became the method of choice to define new differentiation markers. Hybridomas also allowed us to dissect the immune response to a simple antigen and to demonstrate the critical role of somatic mutations in the generation of high affinity antibodies. Now, monoclonal antibodies can be derived and manipulated in vitro, leading to important new developments in therapeutic applications. BioEssays 1999;21:966-973. Copyright 1999 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517870     DOI: 10.1002/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  16 in total

1.  Production and characterisation of cell- and tissue-specific monoclonal antibodies for the flatworm Macrostomum sp.

Authors:  Peter Ladurner; Daniela Pfister; Christof Seifarth; Lukas Schärer; Monika Mahlknecht; Willi Salvenmoser; Regine Gerth; Florentine Marx; Reinhard Rieger
Journal:  Histochem Cell Biol       Date:  2004-11-18       Impact factor: 4.304

2.  The Cellosaurus, a Cell-Line Knowledge Resource.

Authors:  Amos Bairoch
Journal:  J Biomol Tech       Date:  2018-05-10

3.  Isolation of Antibodies to Heparan Sulfate on Glypicans by Phage Display.

Authors:  Heungnam Kim; Mitchell Ho
Journal:  Curr Protoc Protein Sci       Date:  2018-08-09

4.  Construction of Synthetic Phage Displayed Fab Library with Tailored Diversity.

Authors:  Ganggang Huang; Zhenwei Zhong; Shane Miersch; Sachdev S Sidhu; Shin-Chen Hou; Donghui Wu
Journal:  J Vis Exp       Date:  2018-05-01       Impact factor: 1.355

5.  Engineered cell surface expression of membrane immunoglobulin as a means to identify monoclonal antibody-secreting hybridomas.

Authors:  Paul W Price; Elizabeth C McKinney; Youliang Wang; Loren E Sasser; Muthugapatti K Kandasamy; Linda Matsuuchi; Christine Milcarek; Roger B Deal; Deborah G Culver; Richard B Meagher
Journal:  J Immunol Methods       Date:  2009-01-31       Impact factor: 2.303

6.  Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy.

Authors:  Alexander Dömling; Tad A Holak
Journal:  Angew Chem Int Ed Engl       Date:  2014-01-28       Impact factor: 15.336

Review 7.  Concepts for the clinical use of stem cells in equine medicine.

Authors:  Thomas G Koch; Lise C Berg; Dean H Betts
Journal:  Can Vet J       Date:  2008-10       Impact factor: 1.008

Review 8.  From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?

Authors:  Debra L Madden
Journal:  Curr Oncol Rep       Date:  2018-02-07       Impact factor: 5.075

9.  RosettaAntibodyDesign (RAbD): A general framework for computational antibody design.

Authors:  Jared Adolf-Bryfogle; Oleks Kalyuzhniy; Michael Kubitz; Brian D Weitzner; Xiaozhen Hu; Yumiko Adachi; William R Schief; Roland L Dunbrack
Journal:  PLoS Comput Biol       Date:  2018-04-27       Impact factor: 4.475

10.  Antibody production by in vivo RNA transfection.

Authors:  Bizhan Romani; Amirarsalan Kavyanifard; Elham Allahbakhshi
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.